Stryker Co. (NYSE:SYK) Director Sells $78,993,998.08 in Stock

Stryker Co. (NYSE:SYK) Director Ronda E. Stryker sold 201,392 shares of the company’s stock in a transaction dated Friday, January 31st. The stock was sold at an average price of $392.24, for a total transaction of $78,993,998.08. Following the transaction, the director now owns 3,642,075 shares in the company, valued at $1,428,567,498. The trade was a 5.24 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Stryker Stock Up 1.7 %

Shares of SYK opened at $399.01 on Thursday. The firm has a market cap of $152.11 billion, a PE ratio of 51.42, a price-to-earnings-growth ratio of 2.78 and a beta of 0.96. The company has a quick ratio of 1.32, a current ratio of 1.95 and a debt-to-equity ratio of 0.59. The company’s fifty day moving average is $376.87 and its two-hundred day moving average is $364.00. Stryker Co. has a fifty-two week low of $314.93 and a fifty-two week high of $406.19.

Stryker (NYSE:SYK) last posted its quarterly earnings results on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.87 by $0.14. Stryker had a return on equity of 23.58% and a net margin of 13.25%. During the same quarter in the prior year, the firm earned $3.46 earnings per share. Analysts forecast that Stryker Co. will post 13.5 earnings per share for the current year.

Stryker Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st will be given a dividend of $0.84 per share. This represents a $3.36 dividend on an annualized basis and a yield of 0.84%. Stryker’s dividend payout ratio (DPR) is 43.30%.

Analysts Set New Price Targets

Several equities analysts recently weighed in on SYK shares. Citigroup raised their price objective on Stryker from $411.00 to $450.00 and gave the company a “buy” rating in a research note on Wednesday, December 11th. Stifel Nicolaus lifted their price target on Stryker from $400.00 to $440.00 and gave the stock a “buy” rating in a research note on Wednesday, January 29th. Truist Financial increased their price objective on shares of Stryker from $409.00 to $413.00 and gave the company a “hold” rating in a research note on Thursday, January 30th. Royal Bank of Canada upped their price target on shares of Stryker from $425.00 to $435.00 and gave the company an “outperform” rating in a report on Wednesday, January 29th. Finally, StockNews.com downgraded Stryker from a “buy” rating to a “hold” rating in a research report on Thursday, January 30th. Five analysts have rated the stock with a hold rating and sixteen have given a buy rating to the stock. Based on data from MarketBeat.com, Stryker presently has a consensus rating of “Moderate Buy” and a consensus price target of $419.37.

Institutional Investors Weigh In On Stryker

Large investors have recently made changes to their positions in the business. Kohmann Bosshard Financial Services LLC purchased a new stake in Stryker during the 4th quarter worth $25,000. Dunhill Financial LLC boosted its position in shares of Stryker by 94.9% in the third quarter. Dunhill Financial LLC now owns 76 shares of the medical technology company’s stock worth $27,000 after buying an additional 37 shares during the period. Centricity Wealth Management LLC acquired a new stake in shares of Stryker in the fourth quarter valued at about $30,000. BankPlus Trust Department purchased a new stake in shares of Stryker during the 4th quarter valued at about $33,000. Finally, Darwin Wealth Management LLC acquired a new position in Stryker during the 3rd quarter worth approximately $36,000. Institutional investors and hedge funds own 77.09% of the company’s stock.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.